Abstract 1451P
Background
Immune checkpoint blockade (ICB) has significantly impacted the treatment landscape in non-small cell lung cancer (NSCLC). However, this benefit is restricted to a subset of patients. While these results are encouraging, it is crucial to identify those patients who benefit the most from ICB and those who are refractory. Here we investigate the potential utility of longitudinal serum proteomic profiling to identify predictive biomarkers.
Methods
We included 40 metastatic NSCLC patients who received ICB treatment at Hospital del Mar, Barcelona between 2017-2021. Patients were categorized as long-term responders (LTR, n=20) if they had maintained radiologic response for more than 2 years or non-responders (NR, n=20) if they had disease progression at first radiological evaluation. Serum protein levels were assessed longitudinally (before treatment, previous cycle 2) using the Olink® Explore 384 Oncology panel.
Results
LTR had a greater proportion of high PD-L1 expression (p=0.01). Analysis of baseline serum samples showed an increase in LTR of proteins levels related to apoptosis and autophagy (CASP8, ATG4A), TCR signaling pathway (STAT5B, CRACR2A) and myeloid differentiation (ZBTB16, ARG1) (p<0.05 for all proteins). Higher levels of proteins related to immunosuppression and tumorigenesis (PDCD1, TGFBR2, KLK4, KLK6) prior to the second cycle of ICB were associated with poorer response to ICB, with non-responders exhibiting significantly higher levels (p<0.05 for all). Gene set enrichment analysis showed that LTR had an increase in myeloid cell differentiation process, while higher levels of immunoregulatory interactions between lymphoid and non-lymphoid cells were observed in NR (p<0.001 for all).
Conclusions
Our findings suggest that patients with high levels of proteins related to apoptosis, autophagy, TCR signaling, and myeloid differentiation at baseline may identify LTR to ICB. Our study underscores the potential use of baseline and longitudinal assessment of serum proteomics as valuable tools for patient selection who are suitable candidates for ICB. Further studies are needed to validate these findings and establish their potential clinical utility.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Bellosillo Paricio: Financial Interests, Personal, Research Grant: Thermo Fisher, Roche Diagnostics, Roche Pharma, AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Janssen, Novartis; Financial Interests, Personal, Speaker’s Bureau: Janssen, Merck-Serono, Novartis, Qiagen, Thermo Fisher, Pfizer, Bristol Myers Squibb. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20